Investors View Helen Of Troy (HELE) as Flu Season Play

January 10, 2013 10:59 AM EST
Get Alerts HELE Hot Sheet
Price: $92.15 --0%

Rating Summary:
    1 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade HELE Now!
Join SI Premium – FREE
Yesterday Helen Of Troy Ltd (NASDAQ: HELE) reported Q3 EPS that topped estimates by 5 cents. While revenue fell short, shares rose as Wall Street focused on positives. Reports flu season was worse than in previous years also helped support share prices.

Commenting on developments, analyst Lee J. Giordano of Imperial Capital said, "While the external environment for consumer spending continues to be challenging in the U.S. and Europe, Helen of Troy remains well positioned with a diversified product assortment, a strong level of innovation, robust free cash flow generation, and a core competency in acquiring and integrating new brands."

"We believe the healthcare/home environment segment (thermometers, humidifiers, etc.) could potentially benefit from [flu season] in the fiscal fourth quarter (February 2013 end) as the typical flu season stretches from December through March and, most often, peaks in February," added Giordano.

Imperial Capital has an Outperform rating on Helen of Troy (NASDAQ: HELE) with a modified price target of $38.00 (from $35.00).

For an analyst ratings summary and ratings history on Helen of Troy click here. For more ratings news on Helen of Troy click here.

Shares of Helen of Troy closed at $34.43 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Add Your Comment